BioCentury | Aug 17, 2018
Clinical News

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first...
BioCentury | Jan 27, 2017
Company News

ForSight Vision4, Roche deal

Roche acquired ForSight Vision4 for an undisclosed upfront payment and undisclosed development and sales milestones. Roche gained ForSight’s Port Delivery System (PDS) technology. A formulation of Roche’s ranibizumab that uses PDS is in the Phase...
BioCentury | Oct 10, 2016
Finance

M&Allergan

...deals. The recent shopping spree started on Aug. 11 with the acquisition of ophthalmic company ForSight Vision5 Inc....
BioCentury | Aug 22, 2016
Company News

Allergan, ForSight Vision5 deal

...Allergan acquired ForSight Vision5 for $95 million in cash and an undisclosed milestone tied to the launch...
...questions to Allergan, which declined to provide additional financial details. Allergan plc (NYSE:AGN), Dublin, Ireland ForSight Vision5 Inc....
BioCentury | Jun 22, 2016
Company News

Management tracks

...Semba as CMO and Ward Peterson as SVP of preclinical development. Semba was CMO of ForSight Vision5 Inc....
BioCentury | Apr 21, 2014
Financial News

ForSight Vision5 completes venture financing

ForSight Vision5 Inc. , Menlo Park, Calif. Business: Ophthalmic Date completed: 4/16/14 Type: Venture financing Raised: $15 million Investors: H.I.G. BioVentures; Morgenthaler Ventures; Versant Ventures ; Technology Partners; Delphi Ventures WIR Staff Ophthalmic...
BioCentury | Apr 16, 2014
Financial News

ForSight Vision5 raises $15 million in series C

...Ventures; Technology Partners; and Delphi Ventures also participated. H.I.G.'s Aaron Davidson will join ForSight Vision5's board. ForSight Vision5's...
BioCentury | Jan 16, 2012
Company News

ForSight Vision4 Inc., Roche deal

Roche's Genentech Inc. unit said it will make an undisclosed milestone payment to ForSight under a 2010 deal granting Genentech exclusive, worldwide rights to develop and commercialize ForSight's implantable ocular device to deliver anti- VEGF-A...
BioCentury | Jan 14, 2012
Company News

Genentech pays first milestone in ForSight deal

Genentech Inc. said it will make an undisclosed milestone payment to ForSight Vision4 Inc. (Menlo Park, Calif.) under a 2010 deal that gave Genentech exclusive, worldwide rights to develop and commercialize ForSight's implantable ocular device...
Items per page:
1 - 9 of 9
BioCentury | Aug 17, 2018
Clinical News

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first...
BioCentury | Jan 27, 2017
Company News

ForSight Vision4, Roche deal

Roche acquired ForSight Vision4 for an undisclosed upfront payment and undisclosed development and sales milestones. Roche gained ForSight’s Port Delivery System (PDS) technology. A formulation of Roche’s ranibizumab that uses PDS is in the Phase...
BioCentury | Oct 10, 2016
Finance

M&Allergan

...deals. The recent shopping spree started on Aug. 11 with the acquisition of ophthalmic company ForSight Vision5 Inc....
BioCentury | Aug 22, 2016
Company News

Allergan, ForSight Vision5 deal

...Allergan acquired ForSight Vision5 for $95 million in cash and an undisclosed milestone tied to the launch...
...questions to Allergan, which declined to provide additional financial details. Allergan plc (NYSE:AGN), Dublin, Ireland ForSight Vision5 Inc....
BioCentury | Jun 22, 2016
Company News

Management tracks

...Semba as CMO and Ward Peterson as SVP of preclinical development. Semba was CMO of ForSight Vision5 Inc....
BioCentury | Apr 21, 2014
Financial News

ForSight Vision5 completes venture financing

ForSight Vision5 Inc. , Menlo Park, Calif. Business: Ophthalmic Date completed: 4/16/14 Type: Venture financing Raised: $15 million Investors: H.I.G. BioVentures; Morgenthaler Ventures; Versant Ventures ; Technology Partners; Delphi Ventures WIR Staff Ophthalmic...
BioCentury | Apr 16, 2014
Financial News

ForSight Vision5 raises $15 million in series C

...Ventures; Technology Partners; and Delphi Ventures also participated. H.I.G.'s Aaron Davidson will join ForSight Vision5's board. ForSight Vision5's...
BioCentury | Jan 16, 2012
Company News

ForSight Vision4 Inc., Roche deal

Roche's Genentech Inc. unit said it will make an undisclosed milestone payment to ForSight under a 2010 deal granting Genentech exclusive, worldwide rights to develop and commercialize ForSight's implantable ocular device to deliver anti- VEGF-A...
BioCentury | Jan 14, 2012
Company News

Genentech pays first milestone in ForSight deal

Genentech Inc. said it will make an undisclosed milestone payment to ForSight Vision4 Inc. (Menlo Park, Calif.) under a 2010 deal that gave Genentech exclusive, worldwide rights to develop and commercialize ForSight's implantable ocular device...
Items per page:
1 - 9 of 9